Molecular and cellular pharmacological properties of 5- methoxycarbonylamino-N-acetyltryptamine (MCA-NAT): A nonspecific MT3 ligand

Journal of Pineal Research

Volumn 48, Issue 3, 2010, Pages 222-229

  Vincent, Ludwig ^a   Cohen, William ^a   Delagrange, Philippe ^b   Boutin, Jean A ^a   Nosjean, Olivier ^a  

^a INSTITUT DE RECHERCHES SERVIER   (France)

^b INSTITUT DE RECHERCHES SERVIER   (France)

Author keywords

5 Methoxycarbonylamino n acetyltryptamine; Melatonin; Melatonin receptors; Molecular pharmacology; Non MT1; Non MT2 melatonin binding site

Indexed keywords

5 METHOXYCARBONYLAMINO N ACETYLTRYPTAMINE; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; TRYPTAMINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; NONHUMAN; RADIOASSAY;

ANIMALS; BINDING, COMPETITIVE; CELL LINE; CIRCULAR DICHROISM; CRICETINAE; CYCLIC AMP; DRUG INTERACTIONS; FORSKOLIN; HAPLORHINI; HUMANS; INOSITOL PHOSPHATES; MICE; RABBITS; RATS; RECEPTORS, MELATONIN; TRYPTAMINES;

EID: 77749310347     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/j.1600-079X.2010.00746.x     Document Type: Article

References (39)

1. Boutin JA, Audinot V, Ferry G et al. Molecular tools to study melatonin pathways and actions. Trends Pharmacol Sci 2005 26 : 412 419.
2. Delagrange P, Atkinson J, Boutin JA et al. Therapeutic perspectives for melatonin agonists and antagonists. J Neuroendocrinol 2003 15 : 442 448.
3. Delagrange P, Boutin JA. Therapeutic potential of melatonin ligands. Chronobiol Int 2006 23 : 413 418.
4. Jockers R, Maurice P, Boutin JA et al. Melatonin receptors, heterodimerization, signal transduction and binding sites: what's new? Br J Pharmacol 2008 154 : 1182 1195.
5. Becker-André M, Wiesenberg I, Schaeren-Wiemers N et al. Pineal gland hormone melatonin binds and activates an orphan of the nuclear receptor superfamily. J Biol Chem 1994 269 : 28531 28534.
6. Becker-André M, Wiesenberg I, Schaeren-Wiemers N et al. Pineal gland hormone melatonin binds and activates an orphan of the nuclear receptor superfamily. J Biol Chem 1997 272 : 16707.
7. Dubocovich ML. Pharmacology and function of melatonin receptors. FASEB J 1988 2 : 2765 2773.
8. Kennaway DJ, Hugel HM. Melatonin binding sites: are they receptors? Mol Cell Endocrinol 1992 88 : C1 C9.
9. Vella F, Ferry G, Delagrange P et al. NRH:quinone reductase 2: an enzyme of surprises and mysteries. Biochem Pharmacol 2005 71 : 1 12.
10. Molinari EJ, North PC, Dubocovich ML. 2-[125I]iodo-5- methoxycarbonylamino-N-acetyltryptamine: a selective radioligand for the characterization of melatonin ML2 binding sites. Eur J Pharmacol 1996 301 : 159 168.
11. Nosjean O, Ferro M, Coge F et al. Identification of the melatonin-binding site MT3 as the quinone reductase 2. J Biol Chem 2000 275 : 31311 31317.
12. Pintor J, Martin L, Pelaez T et al. Involvement of melatonin MT(3) receptors in the regulation of intraocular pressure in rabbits. Eur J Pharmacol 2001 416 : 251 254.
13. Pintor J, Pelaez T, Hoyle CH et al. Ocular hypotensive effects of melatonin receptor agonists in the rabbit: further evidence for an MT3 receptor. Br J Pharmacol 2003 138 : 831 836.
14. Alarma-Estrany P, Crooke A, Peral A et al. Requirement of intact sympathetic transmission for the ocular hypotensive effects of melatonin and 5-MCA-NAT. Auton Neurosci 2007 137 : 63 66.
15. Alarma-Estrany P, Crooke A, Pintor J. 5-MCA-NAT does not act through NQO2 to reduce intraocular pressure in New-Zealand white rabbit. J Pineal Res 2009 47 : 201 209.
16. Andres-Guerrero V, Alarma-Estrany P, Molina-Martinez IT et al. Ophthalmic formulations of the intraocular hypotensive melatonin agent 5-MCA-NAT. Exp Eye Res 2009 88 : 504 511.
17. Mailliet F, Audinot V, Malpaux B et al. Molecular pharmacology of the ovine melatonin receptor: comparison with recombinant human MT1 and MT2 receptors. Biochem Pharmacol 2004 67 : 667 677.
18. Mailliet F, Ferry G, Vella F et al. Characterization of the melatoninergic MT3 binding site on the NRH:quinone oxidoreductase 2 enzyme. Biochem Pharmacol 2005 71 : 74 88.
19. Furger C, Derick S, Boutin JA et al. Image-free assessment of protein translocation in live cells. Curr Opin Pharmacol 2009 6 : 650 656.
20. Verdonk E, Johnson K, McGuinness R et al. Cellular dielectric spectroscopy: a label-free comprehensive platform for functional evaluation of endogenous receptors. Assay Drug Dev Technol 2006 4 : 609 619.
21. Paul P, Lahaye C, Delagrange P et al. Characterization of 2-[125I]iodomelatonin binding sites in Syrian hamster peripheral organs. J Pharmacol Exp Ther 1999 290 : 334 340.
22. Eison AS, Mullins UL. Melatonin binding sites are functionally coupled to phosphoinositide hydrolysis in Syrian hamster RPMI 1846 melanoma cells. Life Sci 1993 53 : L393 L398.
23. Pickering DS, Niles LP. Expression of nanomolar-affinity binding sites for melatonin in Syrian hamster RPMI 1846 melanoma cells. Cell Signal 1992 4 : 201 207.
24. Chomarat P, Coge F, Guenin SP et al. Cellular knock-down of quinone reductase 2: a laborious road to successful inhibition by RNA interference. Biochimie 2007 89 : 1264 1275.
25. Audinot V, Beauverger P, Lahaye C et al. Structure-activity relationship studies of melanin-concentrating hormone (MCH)-related peptide ligands at SLC-1, the human MCH receptor. J Biol Chem 2001 276 : 13554 13562.
26. Sampaio LF. An unexpected effect of 5-MCA-NAT in chick retinal development. Int J Dev Neurosci 2009 27 : 511 515.
27. Lundmark PO, Pandi-Perumal SR, Srinivasan V et al. Role of melatonin in the eye and ocular dysfunctions. Vis Neurosci 2006 23 : 853 862.
28. Ismail SA, Mowafi HA. Melatonin provides anxiolysis, enhances analgesia, decreases intraocular pressure, and promotes better operating conditions during cataract surgery under topical anesthesia. Anesth Analg 2009 108 : 1146 1151.
29. O'Rourke ST, Hammad H, Delagrange P et al. Melatonin inhibits nitrate tolerance in isolated coronary arteries. Br J Pharmacol 2003 139 : 1326 1332.
30. Lucchelli A, Santagostino-Barbone MG, Tonini M. Investigation into the contractile response of melatonin in the guinea-pig isolated proximal colon: the role of 5-HT4 and melatonin receptors. Br J Pharmacol 1997 121 : 1775 1781.
31. Niles LP, Pickering DS, Sayer BG. HPLC-purified 2-[125I]iodomelatonin labels multiple binding sites in hamster brain. Biochem Biophys Res Commun 1987 147 : 949 956.
32. Pickering DS, Niles LP. Pharmacological characterization of melatonin binding sites in Syrian hamster hypothalamus. Eur J Pharmacol 1990 175 : 71 77.
33. Ferry G, Loynel A, Kucharczyk N et al. Substrate specificity and inhibition studies of human serotonin N-acetyltransferase. J Biol Chem 2000 275 : 8794 8805.
34. Parmentier J, Portevin B, Golsteyn R et al. Synthesis and CHK1 inhibitory potency of Hyemialdisine analogues. Bioorg Med Chem Lett 2009 19 : 841 844.
35. Audinot V, Mailliet F, Lahaye-Brasseur C et al. New selective ligands of human cloned melatonin MT1 and MT2 receptors. Naunyn Schmiedebergs Arch Pharmacol 2003 367 : 553 561.
36. Lagneux C, Joyeux M, Demenge P et al. Protective effects of melatonin against ischemia-reperfusion injury in the isolated rat heart. Life Sci 2000 66 : 503 509.
37. Kopp C, Vogel E, Rettori M et al. Anxiolytic-like properties of melatonin receptor agonists in mice: involvement of mt1 and/or MT2 receptors in the regulation of emotional responsiveness. Neuropharmacology 2000 39 : 1865 1871.
38. Serle JB, Wang RF, Peterson WM et al. Effect of 5-MCA-NAT, a putative melatonin MT3 receptor agonist, on intraocular pressure in glaucomatous monkey eyes. J Glaucoma 2004 13 : 385 388.
39. Tamura EK, Silva CL, Markus RP. Melatonin inhibits endothelial nitric oxide production in vitro. J Pineal Res 2006 41 : 267 274.